Risk of breast cancer in patients with lymphangioleiomyomatosis

Cancer Epidemiol. 2019 Aug;61:154-156. doi: 10.1016/j.canep.2019.06.004. Epub 2019 Jun 28.

ABSTRACT

Lymphangioleiomyomatosis (LAM) is a rare metastasizing pulmonary disease that shares some clinical, cellular, and molecular similarities with metastatic breast cancer to lung. LAM cells have been identified circulating in various body fluids of patients and, intriguingly, diverse evidence indicates that these cells may originate from a different organ to the lung. Following on from these observations, we hypothesized the existence of a common risk basis between LAM and breast cancer, and suggested increased risk of breast cancer among LAM patients. Here, by studying two additional LAM cohorts with more detailed epidemiological, life-style, and disease-related data, we show consistent results; a potential excess of estrogen-receptor-positive young breast cancer cases in LAM. This observation further suggests the need of prospective studies to precisely assess the association between both diseases.

PMID:31260937 | DOI:10.1016/j.canep.2019.06.004